Lloyd Laboratories

Lloyd Laboratories is a prominent pharmaceutical manufacturer and contract development and manufacturing organization (CDMO) headquartered in the Philippines, with extensive operations in India and Indonesia. Founded in 1989, the company produces a diverse range of pharmaceutical products including tablets, capsules, liquid orals, ointments, and sterile injectables across major therapeutic areas such as cardiovascular, anti-diabetic, and respiratory health. It is a leading provider of toll manufacturing services for numerous multinational and local pharmaceutical companies, operating state-of-the-art cGMP-compliant facilities. Lloyd Laboratories is recognized for its technical expertise in advanced drug delivery systems, including sustained-release formulations, dry powder inhalers, and nasal sprays. In 2023, the company entered into a strategic joint venture with U.S.-based DifGen Pharmaceuticals to expand its reach into high-value generic markets, particularly in the United States. With over 800 employees and a corporate turnover exceeding $100 million, the company remains a key player in the Asian pharmaceutical landscape.